학력 및 경력사항

• 서울대학교 의과대학 대학원 박사
• 서울대학교 의과대학 대학원 석사
• 서울대학교 의과대학 의학과 졸업

• 2016-현재  | 이화여자대학교 의과대학 내과학교실 이대목동병원 부교수
• 2012-2016  | 서울대학교병원운영 서울특별시 보라매병원 임상교수
• 2010-2012  |  국립암센터 간암센터 전문의
• 2010  | 소화기내과 분과전문의
• 2008-2010  | 서울대학교병원 소화기내과 임상강사
• 2009  | 소화기내시경 세부전문의
• 2008  | 미국의사면허 (ECFMG certificate)
• 2005  | 내과 전문의
• 2001-2005  | 서울대학교병원 내과 전공의
• 2000-2001  | 서울대학교병원 수련의

• 2017-현재  | 대한간학회 섭외위원
• 2018  | 대한간암학회-국립암센터 간세포암종 진료 가이드라인 개정위원
• 2017-2018  | 대한간암학회 연구이사
• 2016-2017  | 대한간암학회 학술위원
• 2014  | 대한간암학회-국립암센터 간세포암종 진료 가이드라인 개정위원
• 2013-2014  |  대한간암학회 학술위원
• 2011  | 대한간학회 만성 B형 간염 진료 가이드라인 개정위원
• 2010-2011  | 대한간학회 섭외위원

•  An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.  JOURNAL OF HEPATOLOGY. 2022, v.76 no.2, 311-318. 
•  Association of Chronic Hepatitis B Infection and Antiviral Treatment with the Development of the Extrahepatic Malignancies: A Nationwide Cohort Study.  Journal of Clinical Oncology. 2022, v.392, 1285. 
•  Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease.  Clinical Gastroenterology and Hepatology. 2022. 
•  Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B.  Clinical Gastroenterology and Hepatology. 2022, v.20 no.6, 1343-1.35E19. 
•  Platelet-to-White Blood Cell Ratio Is Associated with Adverse Outcomes in Cirrhotic Patients with Acute Deterioration.  Journal of Clinical Medicine. 2022, v.11 no.9, 2463. 
•  Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B.  CANCERS. 2021, v.13 no.14, 3424. 
•  Differential TM4SF5-mediated SIRT1 modulation and metabolic signaling in nonalcoholic steatohepatitis progression.  Journal of Pathology. 2021, v.253 no.1, 55-67. 
•  Direct-Acting Antivirals Improve Treatment Outcomes in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Nationwide, Multi-center, Retrospective Cohort Study.  Digestive Diseases and Sciences. 2021, v.66 no.7, 2427-2438. 
•  Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma.  YONSEI MEDICAL JOURNAL. 2021 , 12-20. 
•  Recent advances in nonalcoholic fatty liver disease metabolomics.  CLINICAL AND MOLECULAR HEPATOLOGY. 2021, v.27 no.4, 553-559. 
•  Treatment of direct oral anticoagulants in patients with liver cirrhosis and portal vein thrombosis.  CLINICAL AND MOLECULAR HEPATOLOGY. 2021, v.27 no.4, 535-552. 
•  A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function.  BMC CANCER. 2020, v.20 no.1, 504. 
•  Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.  GUT. 2020, v.69 no.12, 2214-2222. 
•  Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease.  BMC NEPHROLOGY. 2020, v.21 no.1, 50. 
•  Relative fat mass at baseline and its early change may be a predictor of incident nonalcoholic fatty liver disease.  Scientific Reports. 2020, v.10 no.1, 17491. 
•  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.  KOREAN JOURNAL OF RADIOLOGY. 2019, v.20 no.7, 1042-. 
•  Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean subjects.  PLOS ONE. 2019, v.14 no.3, e0213692. 
•  Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.  JOURNAL OF HEPATOLOGY. 2019, v.70 no.3, 412-422. 
•  Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.  JOURNAL OF HEPATOLOGY. 2019, v.70 no.4, 684-691. 
•  The Efficacy of Cone-Beam CT–Based Liver Perfusion Mapping to Predict Initial Response of Hepatocellular Carcinoma to Transarterial Chemoembolization.  Journal of Vascular and Interventional Radiology. 2019, v.30 no.3, 358-369. 
•  Tumor marker-based definition of the transarterial chemoembolization-refractoriness in intermediate-stage hepatocellular carcinoma: A multi-cohort study.  Cancers. 2019, v.11 no.11, 1721. 
•  A Model for Adaptive Decision Making of 'Ablate-and-Wait' Versus Transplantation in Patients with Hepatocellular Carcinoma.  Journal of Clinical Gastroenterology. 2018, v.52 no.7, 655-661. 
•  Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality.  Scientific Reports. 2018, v.8 no.1, 13651. 
•  Efficacy of granulocyte colony stimulating factor in patients with severe alcoholic hepatitis with partial or null response to steroid (GRACIAH trial): study protocol for a randomized controlled trial.  TRIALS. 2018, v.19, 696. 
•  Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area.  ALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2018, v.47 no.11, 1490-1501. 
•  Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study.  BMC CANCER. 2018, v.18. 
•  Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study.  BMC CANCER. 2018, v.18. 
•  Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study.  JOURNAL OF MEDICAL VIROLOGY. 2018, v.90 no.10, 1593-1603. 
•  Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib.  CANCER RESEARCH AND TREATMENT. 2018, v.50 no.2, 366-373. 
•  Current immunotherapeutic strategies in hepatocellular carcinoma: Recent advances and future directions.  Therapeutic Advances in Gastroenterology. 2017, v.10 no.10, 805-814. 
•  Noninvasive prediction of hemodynamic response to carvedilol therapy for primary prophylaxis in cirrhotic patients with esophageal varices: a prospective study.  JOURNAL OF HEPATOLOGY. 2017, v.66 no.1, S47-S47. 
•  Oral Medications Enhance Adherence to Surveillance for Hepatocellular Carcinoma and Survival in Chronic Hepatitis B Patients.  PLOS ONE. 2017, v.12 no.1. 
•  소라페닙 치료 실패 후 반복적인 경동맥 화학색전술로 장기 생존한 1예.  대한간암학회지. 2017, v.17 no.1, 82~87. 
•  A Novel Biomarker-Based Model for the Prediction of Response to Sorafenib and Overall Survival for Advanced Hepatocellular Carcinoma: A Prospective Cohort Study.  HEPATOLOGY. 2016, v.63 no.1 SUPP, 634A-634A. 
•  Changes in Noninvasive Liver Fibrosis Indices and Spleen Size During Chemotherapy Potential Markers for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome.  MEDICINE. 2016, v.95 no.2, e2454. 
• Kim HY, Chang Y, Park JY, et al. Characterization of acute-on-chronic liver failure and prediction of mortality in Asian patients with active alcoholism.  Journal of gastroenterology and hepatology. 2016, v.31 no.2, 427-433. 
• Park S, Kim HY, Kim H, et al.. Changes in Noninvasive Liver Fibrosis Indices and Spleen Size During Chemotherapy: Potential Markers for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome.  Medicine. 2016;95:e2454. 
• Yu SJ, Kim W, Kim D, et al. Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.  Medicine. 2015;94:e2159. 
• Lee JH, Cho Y, Kim HY, et al. Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria.  Annals of surgery. 2016, v.263 no.5, 842-850. 
• Kim HY, Jin EH, Kim W, et al. The Role of Spleen Stiffness in Determining the Severity and Bleeding Risk of Esophageal Varices in Cirrhotic Patients.  Medicine. 2015;94:e1031. 
• Chung KH, Kim W, Kim BG, et al.. Hepatitis B Surface Antigen Quantification across Different Phases of Chronic Hepatitis B Virus Infection Using an Immunoradiometric Assay.  Gut and liver. 2015, v.9 no.5, 657-664. 
• Hwang SY, Yu SJ, Lee JH, Kim HY, Kim YJ. Reduction of oxidative stress attenuates lipoapoptosis exacerbated by hypoxia in human hepatocytesv.  Int J Mol Sci. 2015;16:3323-34. . 
• Kim HY, Kim W. Chemotherapy-related reactivation of hepatitis B infection: updates in 2013.  World journal of gastroenterology : WJG. 2014;20:14581-8. . 
• Kim HY, Park JW. Clinical Trials of Combined Molecular Targeted Therapy and Locoregional Therapy in Hepatocellular Carcinoma: Past, Present, and Future.  Liver cancer. 2014;3:9-17. 
• Kim HY, Yoon JH, Lee HS, et al..  MicroRNA-196A-2 polymorphisms and hepatocellular carcinoma in patients with chronic hepatitis B.  Journal of medical virology. 2014;86:446-53. 
• Lee M, Oh S, Lee HJ, et al. Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy.  Journal of viral hepatitis. 2014;21:873-81. 
• Lee JH, Kim HY, Kim YJ, Yoon JH, Chung JW,Lee HS.  BCLC System Provides the Best Discrimination Ability for Survival of Untreated Hepatocellular Carcinoma Patients in an HBV-endemic Area.  Journal of gastroenterology and hepatology. 2014. 
• Lee M, Kim W, Choi Y, et al.  Spontaneous evolution in bilirubin levels predicts liver-related mortality in patients with alcoholic hepatitis.  PLoS One. 2014;9:e100870. 
• Kim HY, Park JW, Joo J, et al. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.  Journal of gastroenterology and hepatology. 2013;28:1756-61. 
• Chung GE, Kim W, Lee KL, et al. Add-on adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B.  Digestive diseases and sciences. 2011;56:2130-6. 
• Joo SK, Kim JH, Oh S, et al. Prospective Comparison of Noninvasive Fibrosis Assessment to Predict Advanced Fibrosis or Cirrhosis in Asian Patients With Hepatitis C.  Journal of clinical gastroenterology. 2015, v.49 no.8, 697-704. 
• Seo JY, Kim W, Kwon JH, et al. Noninvasive fibrosis indices predict intrahepatic distant recurrence of hepatitis B-related hepatocellular carcinoma following radiofrequency ablation.  Liver international : official journal of the International Association for the Study of the Liver. 2013;33:884-93. 
• Kim YJ, Kim HY, Lee JH, et al. A genome-wide association study identified new variants associated with the risk of chronic hepatitis B.  Human molecular genetics. 2013;22:4233-8. 
• Kim JW, Jeong JB, Lee KL, et al. Comparison of clinical outcomes between endoscopic and radiologic placement of self-expandable metal stent in patients with malignant colorectal obstruction.  The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi. 2013;61:22-9. 
• Jun DW, Kim BI, Cho YK, et al. Efficacy and safety of entecavir plus carnitine complex (GODEX(R)) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study.  Clinical and molecular hepatology. 2013;19:165-72. 
• Park JW, Koh YH, Kim HB, et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.  Journal of hepatology. 2012;56:1336-42. 
• Kim HY, Kwon HD, Jang TS, Lim J, Lee HS. Mathematical Modeling of Triphasic Viral Dynamics in Patients with HBeAg-Positive Chronic Hepatitis B Showing Response to 24-Week Clevudine TherapyMathematical Modeling of Triphasic Viral Dynamics in Patients with HBeAg-Positive Chronic Hepatitis B Showing Response to 24-Week Clevudine Therapy.  PLOS ONE. 2012;7:e50377. 
• Kim HY, Park JW, Joo J, et al. Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma.  Journal of gastroenterology and hepatology. 2012;27:1051-6. 
• Kim HY, Park JW, Nam BH, et al.  Survival of patients with advanced hepatocellular carcinoma: Sorafenib versus other treatments.  Journal of gastroenterology and hepatology. 2011;26:1612-8. 
• Kim HY, Park JW.  Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.  Dig Dis. 2011;29:303-9. 
• Chung GE, Yoon JH, Lee JH, et a. Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth.  Oncology reports. 2011;25:1739-46. 
• Kwak MS, Lee JH, Chung GE, et al. ow P2/MS value is an independent risk factor for early recurrence of hepatocellular carcinoma after radiofrequency ablation therapy.  Hepato-gastroenterology. 2011;58:147-52. 
• Lee JH, Yoon JH, Lee YJ, et al. Mesalamine-induced B7-H1 expression on hepatic stellate cells attenuates autoimmune liver injury.  Hepatology research : the official journal of the Japan Society of Hepatology. 2011;41:79-86. 
• Lee JH, Chung GE, Yu SJ, et al. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma.  Journal of clinical gastroenterology. 2011;45:69-75. 
• Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival.  Radiology. 2011;258:627-34. 
• Dig Dis 2011;29:303-9. . Putative association of transforming growth factor-alpha polymorphisms with clearance of hepatitis B virus and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.  Journal of viral hepatitis. 2010;17:518-26. 
• Lee JH, Yoon JH, Yu SJ, et al. Retinoic acid and its binding protein modulate apoptotic signals in hypoxic hepatocellular carcinoma cells.  Cancer letters. 2010;295:229-35. 

• [약업신문] "C형 간염, 치료 가능하지만 검진 통해 빠른 치료가 더 중요" 2021-12-26
• [스포츠조선] 이대목동병원·서울대병원 연구팀, AI 기반 만성B형간염 환자 간암 예측모형 개발 2021-10-13
• [파이낸셜뉴스] 저체중이어도 지방 많으면 '지방간' 위험...탄수화물 줄여야 [질환과 음식] 2020-11-14
• [연합뉴스] "저체중·정상체중도 지방량 증가하면 지방간 위험 커져" 2020-11-09

• [건강강좌영상] 비알코올지방간질환, 알고 싸우면 이긴다! 2019-06-22